Currentsierra health and lifePolicy 2026T0629J

Percutaneous Neuroablation for Pancreatic Cancer Pain, Severe Cancer Pain, and Trigeminal Neuralgia

Defines UnitedHealthcare Commercial and Individual Exchange coverage stance for percutaneous neuroablation used to treat pancreatic cancer pain, severe cancer pain, and trigeminal neuralgia; applies to providers and claims adjudicators for affected members.

Policy Summary

Payersierra health and life

PolicyPercutaneous Neuroablation for Pancreatic Cancer Pain, Severe Cancer Pain, and Trigeminal Neuralgia

Policy CodePolicy 2026T0629J

Change TypeNo material change

Effective DateJan 1, 2026

Next Review Date

Key ActionRefer to member specific benefit plan and use InterQual neuroablation criteria when requesting authorization for percutaneous neuroablation.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

3indications named as proven

InterQualexternal criteria

4CPT codes listed

Commercial/Exchangeplans

Coverage Criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Covered Indications (requires InterQual criteria)

Covered when meeting referenced clinical criteria

Primary coverage statement: Percutaneous Neuroablation is proven and medically necessary for the treatment of pancreatic cancer pain, severe cancer pain, and Trigeminal Neuralgia.

For specific medical necessity clinical coverage criteria, refer to the InterQual CP: Procedures, Neuroablation, Percutaneous.

These coverage criteria do not address cold neuroablation techniques. Cold neuroablation (also referred to as cryoneurolysis or cryoablation) is considered experimental and is currently not addressed by these criteria.

Conservative Treatment Requirements

Trial of pharmacotherapy expected prior to procedural intervention for TN (see InterQual).

Trial of pharmacotherapy expected prior to procedural intervention for trigeminal neuralgia (per referenced criteria)

Conservative therapy requirement: A trial of appropriate pharmacotherapy (e.g., analgesic and/or antiepileptic drugs) is expected prior to considering percutaneous neuroablation for Trigeminal Neuralgia; neuroablation may be considered when TN is refractory to pharmacotherapy per the referenced InterQual criteria.

Refer to InterQual CP: Procedures, Neuroablation, Percutaneous for specific medical necessity criteria and documentation expectations.

Provider Actions and Authorization

Prior Authorization

Authorization guided by InterQual and plan documents

Prior authorization and clinical review for procedures are guided by InterQual criteria and the member-specific benefit plan document. Before submission, verify that the requested service aligns with the member's benefit plan — the benefit document governs if there is any conflict. Medical records may be required to determine whether the member meets clinical criteria; lack of adequate documentation may delay review or result in denial.

Verify member-specific benefit plan for coverage terms.
Use InterQual criteria when applicable for clinical decision support.
Anticipate requests for medical records during review.

Step Therapy

Conservative therapy expectation for TN

For Trigeminal Neuralgia (TN) cases, conservative therapy is expected prior to approval of invasive neuroablative procedures. Document trials of first-line medical management (e.g., analgesic and antiepileptic drugs) and response to therapy. If medical therapy was intolerable or contraindicated, include supporting clinical rationale and records.

Document trial of at least one appropriate antiepileptic or analgesic medication and duration/response.
If medications were not effective, provide objective evidence of refractory pain or intolerable side effects.
Include rationale when bypassing conservative therapy (e.g., contraindication, prior surgical interventions).

Documentation Required

Medical records and benefit document requirement

Benefit coverage is determined by the member specific benefit plan document and applicable laws. Medical records documentation may be required to assess whether the member meets the clinical criteria for coverage but does not guarantee coverage of the service requested. Provide complete medical records that directly support the clinical indications and prior treatment attempts.

Include office notes, medication trials (names, doses, dates), imaging reports, prior procedure notes, and pain assessments.
Ensure records clearly document diagnosis, severity, and prior conservative treatments.
Attach copies of any prior authorization decisions or relevant benefit plan provisions, if available.

Denial Risk

Documentation-related denial risk

Insufficient or missing documentation that fails to demonstrate medical necessity, prior conservative therapy, or member benefit eligibility increases the risk of denial. Denials can occur if requested services are not supported by the member's benefit plan or if clinical criteria documented in records are incomplete.

Incomplete medication history or lack of documented treatment failure may lead to denial.
Failure to verify member benefits or to submit necessary records may result in claim or authorization denial.
Respond promptly to information requests to avoid adverse determinations based on incomplete records.

Definitions

Percutaneous Neuroablation — definition and scope

DefinitionPercutaneous Neuroablation: a procedure that destroys or damages neural tissue to relieve pain; methods include chemical neuroablation (percutaneous administration of phenol or alcohol) and radiofrequency thermal neuroablation.

Chemical methodChemical neuroablation involves percutaneous administration of phenol or alcohol around a nerve to denervate it.

Radiofrequency methodRadiofrequency neuroablation is a type of thermal neuroablation utilizing heat.

Cold neuroablation statusCold neuroablation (e.g., cryoneurolysis, cryoablation) is considered experimental and is not addressed by these criteria.

Trigeminal Neuralgia — definition and initial management

DefinitionTrigeminal Neuralgia (TN): a neuropathic pain syndrome affecting the trigeminal nerve, characterized by severe electric shock–like painful episodes in one or more divisions.

Typical initial treatmentFirst-line treatment commonly involves medical management with analgesic and/or antiepileptic drugs.

When procedures consideredProcedural or minimally invasive interventions (including neuroablation when appropriate) may be considered when TN is refractory to pharmacotherapy.

64600	Destruction by neurolytic agent, trigeminal nerve; supraorbital, infraorbital, mental, or inferior alveolar branch.
64605	Destruction by neurolytic agent, trigeminal nerve; second and third division branches at foramen ovale.
64610	Destruction by neurolytic agent, trigeminal nerve; second and third division branches at foramen ovale under radiologic monitoring.
64620	Destruction by neurolytic agent, intercostal nerve.
64640	Destruction by neurolytic agent; other peripheral nerve or branch.

OpenPayer

Percutaneous Neuroablation for Pancreatic Cancer Pain, Severe Cancer Pain, and Trigeminal Neuralgia

Coverage Criteria

Conservative Treatment Requirements

Procedure Codes

Provider Actions and Authorization

Definitions

Imaging and Monitoring Requirements

Background

Not Covered